To evaluate the survival benefit associated with Zemplar therapy as compared to Calcijex for the treatment of secondary hyperparathyroidism in subjects with Stage V chronic kidney disease on hemodialysis as measured by time to death.

Official Title

A Phase IV, Prospective, Randomized, Active-Controlled, Double-Blind, Double-Dummy, Multi-Center Study to Evaluate the Survival Benefits of Zemplar Relative to Calcijex in Subjects with Stage V Chronic Kidney Disease on Hemodialysis

Conditions

End-Stage Kidney Disease

Study Type

Observational

Study Design

Natural History, Longitudinal, Defined Population, Prospective Study

Further Details

Study Start

April 2003

Eligibility & Criteria

Criteria:- Stage V Chronic Kidney Disease Patients on Hemodialysis requiring treatment for secondary hyperparathyroidism with vitamin D therapy

Total Enrolment

2200

Contact Details

Julie Rock 847-937-3286 (US Only) or contact via email julie.rock@abbott.com